Figure 1.
Incident cases of neovascular age-related macular degeneration (AMD) were derived by multiplying the number of individuals in each age group and gender by the respective incidences in the Blue Mountains Eye Study. Incident cases of neovascular AMD from 1 year were in the model for 2 years. Among individuals with AMD in one eye, 33% were estimated to have AMD in the fellow eye at baseline [3], [5], [14]. SI: simulation interval; VA: visual acuity; vPDT: photodynamic therapy with verteporfin.
Table 1.
The Australian population aged 60 years or over in June 2010; distribution by age and gender.
Table 2.
Specification of the model parameters.
Table 3.
Blindness and visual impairment outcomes in patients with neovascular age-related macular degeneration with and without monthly treatment with ranibizumab.
Figure 2.
The impact of neovascular age-related macular degeneration lesion type on the cases of blindness (best-corrected visual acuity in better-seeing eye worse than 6/60) avoided using a monthly ranibizumab scenario compared with a no-treatment scenario. In the base analysis, 1622 cases of legal blindness were avoided with monthly ranibizumab, as indicated by the vertical line. aEligible for PDT and ranibizumab. bIneligible for any treatment. cEligible for ranibizumab, but not for PDT. PDT: photodynamic therapy.
Figure 3.
The impact of neovascular age-related macular degeneration lesion type on the cases of visual impairment (best-corrected visual acuity in better-seeing eye worse than 6/12) avoided using a monthly ranibizumab scenario compared with a no-treatment scenario. In the base analysis, 1774 cases of visual impairment were avoided with monthly ranibizumab, as indicated by the vertical line. aEligible for PDT and ranibizumab. bIneligible for any treatment. cEligible for ranibizumab, but not for PDT. PDT: photodynamic therapy.